Inclusion Criteria:

          -  Adults ≥18 years old with histologically proven, moderate to well-differentiated G1/2
             pancreatic or midgut NETs with Ki-67 < 20%;

          -  The presence of somatostatin receptor avidity suitable for PRRT demonstrated on
             68Ga-octreotate PET scan;

          -  Progressive advanced/metastatic disease that has progressed during or after ≤ 2 prior
             systemic therapies;

          -  Unresectable disease, determined by an appropriately specialized surgeon or deemed not
             suitable for liver directed therapies where liver is the only site of disease;

          -  ECOG performance status 0-2;

          -  Ability to swallow oral medication;

          -  Adequate renal function (measured creatinine clearance > 50 ml/min by DTPA or
             51CR-EDTA), bone marrow function (Hb > 9 g/d/L, ANC > 1.5 x109L, and platelets > 100 x
             10/L);

          -  Adequate liver function (serum total bilirubin ≤ 1.5 x ULN, and Alanine
             aminotransferase (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase (ALP) ≤
             2.5 x ULN (≤ 5 x ULN for patients with liver metastases)). INR ≤ 1.5 (or on a stable
             dose of LMW heparin for >2 weeks at time of enrolment .);

          -  Life expectancy of at least 9 months;

          -  Study treatment both planned and able to start within 28 days of randomisation; )

          -  Willing and able to comply with all study requirements, including treatment, timing
             and/or nature of required assessments;

          -  Signed, written informed consent.

        Exclusion Criteria:

          -  Primary NETs other than small bowel (midgut) or pancreatic NETs;

          -  Cytotoxic chemotherapy, targeted therapy, or biotherapy within the last four weeks;

          -  Prior intrahepatic 90Y microspheres, such as SIR-Spheres in the past six months;

          -  Prior Peptide Receptor Radionuclide Therapy;

          -  Major surgery/surgical therapy for any cause within one month;

          -  Surgical therapy of loco-regional metastases within the last three months prior to
             randomisation;

          -  Uncontrolled metastatic disease to the central nervous system. To be eligible, CNS
             metastases should have been treated with surgery and/or radiotherapy and the patient
             should have been receiving a stable dose of steroids for at least 2 weeks prior to
             randomisation, with no deterioration in neurological symptoms during this time;

          -  Poorly controlled concurrent medical illness. E.g. unstable diabetes (Note: optimal
             glycaemic control should be achieved before starting trial therapy); Symptomatic NYHA
             class III or IV congestive cardiac failure, myocardial infarction within 6 months of
             start of the study, serious uncontrolled cardiac arrhythmia, unstable angina, or any
             other clinically significant cardiac disease;

          -  History of other malignancies within 5 years except where treated with curative intent
             AND with no current evidence of disease AND considered not to be at risk of future
             recurrence Patients with a past history of adequately treated carcinoma-in-situ, basal
             cell carcinoma of the skin, squamous cell carcinoma of the skin, or superficial
             transitional cell carcinoma of the bladder are eligible;

          -  Any uncontrolled known active infection, including chronic active hepatitis B,
             hepatitis C, or HIV. Testing for these is not mandatory unless clinically indicated.
             Participants with known Hepatitis B/C infection will be allowed to participate
             providing evidence of viral suppression has been documented and the patient remains on
             appropriate anti-viral therapy;

          -  Impairment of gastrointestinal function or gastrointestinal disease that may
             significantly alter the absorption of capecitabine/temozolomide (e.g., ulcerative
             disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or
             substantial small bowel resection);

          -  Presence of any psychological, familial, sociological or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule,
             including alcohol dependence or drug abuse;

          -  Pregnancy, lactation, or inadequate contraception. Women must be post-menopausal,
             infertile, or use a reliable means of contraception. Women of childbearing potential
             must have a negative pregnancy test done within 7 days prior to registration. Men must
             have been surgically sterilised or use a (double if required) barrier method of
             contraception .